TTY Biopharm Company Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2,521	2,773	2,621	2,357	2,222
Short-Term Investments	467.74	309.02	195.54	326.86	372.65
Cash & Short-Term Investments	2,989	3,082	2,817	2,684	2,595
Cash Growth	-3.02%	9.41%	4.93%	3.44%	1.12%
Accounts Receivable	1,518	1,354	1,344	1,227	1,138
Other Receivables	36.46	23.18	28.81	29.68	13.62
Receivables	1,554	1,377	1,373	1,257	1,151
Inventory	1,389	1,270	1,096	1,039	955.01
Prepaid Expenses	-	-	79.02	49.89	46.96
Other Current Assets	76.88	64.58	6.36	5.37	1.15
Total Current Assets	6,009	5,793	5,370	5,035	4,749
Property, Plant & Equipment	2,199	2,246	2,287	2,433	2,519
Long-Term Investments	2,205	1,940	1,578	1,496	1,432
Goodwill	247.9	247.9	-	-	-
Other Intangible Assets	177.27	123.44	164.01	250.75	124.9
Long-Term Deferred Tax Assets	65.8	58.52	48.71	47.1	63.72
Other Long-Term Assets	444.8	453.25	426.94	337.89	407.19
Total Assets	11,348	10,863	9,875	9,601	9,296
Accounts Payable	270.78	326.16	294.66	289.4	187.27
Short-Term Debt	700	1,200	1,450	1,370	1,711
Current Portion of Long-Term Debt	500	400	-	418.85	407.91
Current Portion of Leases	8.35	0.93	5.86	3.92	7.62
Current Income Taxes Payable	323.68	228.8	156.97	149.52	150.39
Current Unearned Revenue	53.7	34.34	14.23	33.13	39.77
Other Current Liabilities	783.33	672.18	662.02	652.62	547.55
Total Current Liabilities	2,640	2,862	2,584	2,917	3,052
Long-Term Debt	-	100	400	9.6	4.15
Long-Term Leases	7.4	10.2	3.05	3.04	14.16
Pension & Post-Retirement Benefits	17.01	17.54	27.4	40.81	52.6
Long-Term Deferred Tax Liabilities	363.19	359.24	318.75	305.44	260.52
Other Long-Term Liabilities	269.3	2.44	35.83	91.03	146.23
Total Liabilities	3,297	3,352	3,369	3,367	3,529
Common Stock	2,487	2,487	2,487	2,487	2,487
Additional Paid-In Capital	317.56	317.04	316.62	312.18	311.88
Retained Earnings	4,427	3,888	3,182	2,925	2,568
Comprehensive Income & Other	7.18	58.69	-43.79	-64.78	-198.07
Total Common Equity	7,238	6,750	5,941	5,658	5,168
Minority Interest	812.93	760.49	564.8	574.86	599.38
Shareholders' Equity	8,051	7,511	6,506	6,233	5,767
Total Liabilities & Equity	11,348	10,863	9,875	9,601	9,296
Total Debt	1,216	1,711	1,859	1,805	2,145
Net Cash (Debt)	1,773	1,371	957.65	878.78	450
Net Cash Growth	29.36%	43.11%	8.97%	95.28%	6.52%
Net Cash Per Share	7.11	5.50	3.84	3.53	1.81
Filing Date Shares Outstanding	248.65	248.65	248.65	248.65	248.65
Total Common Shares Outstanding	248.65	248.65	248.65	248.65	248.65
Working Capital	3,369	2,931	2,787	2,118	1,698
Book Value Per Share	29.11	27.15	23.89	22.76	20.78
Tangible Book Value	6,813	6,379	5,777	5,408	5,043
Tangible Book Value Per Share	27.40	25.65	23.23	21.75	20.28
Land	902.9	902.9	902.9	902.9	902.9
Buildings	1,495	1,479	1,461	1,432	1,420
Machinery	1,443	1,446	1,432	1,418	1,359
Construction In Progress	71.53	0.59	8.95	77.09	95

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.